As evidenced by numerous studies, anti-diabetic pharmaceuticals, including gliptins [18], incretin mimetics [19], and glifozines [20], as well as renin-angiotensin-system blockers [21, 22], also approved for diabetic nephropathy, cause a reduction in NHE3 expression and inhibit its activity. Here, SLC9A3 is linked to diabetic kidney disease.